Drug survival of biologic therapies for palmoplantar pustulosis: A nationwide study.

Bertelsen, T; Egeberg, A; Skov, L; Rasmussen, M; Bryld, L; Funding, A; Ajgeiy, K; Thein, D

Bertelsen, T; Egeberg, A; Skov, L; Rasmussen, M; Bryld, L; Funding, A; Ajgeiy, K; Thein, D.

Affiliation

Bertelsen T; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Egeberg A; DERMBIO, Denmark.
Skov L; DERMBIO, Denmark.
Rasmussen M; Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Bryld L; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Funding A; DERMBIO, Denmark.
Ajgeiy K; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Thein D; Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark.

J Eur Acad Dermatol Venereol ; 38(2): 332-339, 2024 Feb.

Article in En | MEDLINE | ID: mdl-37859514

Subject(s)

Biological Products; Psoriasis; Humans; Ustekinumab/therapeutic use; Ustekinumab/adverse effects; Adalimumab/adverse effects; Prospective Studies; Psoriasis/drug therapy; Psoriasis/chemically induced; Biological Factors/therapeutic use; Biological Therapy; Biological Products/therapeutic use; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Biological Products Limits: Humans Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2024 Document type: Article Affiliation country: Denmark Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google